Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4251003 tucatinib + trastuzumab in HER2-altered solid tumors
2024-511481-37-00Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of tucatinib and trastuzumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), breast cancer and 6 more (2 arms), sponsored by Seagen Inc. Primary endpoint: Confirmed objective response rate (ORR). Started Apr 2024; status: completed.
02
Drugs
tucatinibtrastuzumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)breast cancerCervical Cancer (CC)primary brain neoplasm
Beyond the preview
Go deeper on 2024-511481-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511481-37-00.